{"name":"Eyegate Pharmaceuticals, Inc.","slug":"eyegate-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":10780397,"netIncome":-10835154,"cash":8696570,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dexamethasone Phosphate Ophthalmic Solution","genericName":"Dexamethasone Phosphate Ophthalmic Solution","slug":"dexamethasone-phosphate-ophthalmic-solution","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EGP-437 with EyeGate® II System","genericName":"EGP-437 with EyeGate® II System","slug":"egp-437-with-eyegate-ii-system","indication":"Macular edema associated with retinal vein occlusion","status":"phase_2"}]}],"pipeline":[{"name":"Dexamethasone Phosphate Ophthalmic Solution","genericName":"Dexamethasone Phosphate Ophthalmic Solution","slug":"dexamethasone-phosphate-ophthalmic-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EGP-437 with EyeGate® II System","genericName":"EGP-437 with EyeGate® II System","slug":"egp-437-with-eyegate-ii-system","phase":"phase_2","mechanism":"EGP-437 is a corticosteroid delivered directly to the eye via the EyeGate® II iontophoresis system to reduce ocular inflammation.","indications":["Macular edema associated with retinal vein occlusion","Uveitis and other posterior segment inflammatory conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTHNDR2RoWGUwU3lJeHRocVBKaW5WQ09zM2xwWEQzS1JTMndGcFhUcDV0OUpsNTBycEgwVUY3YUJjZ01EOEJJOXdzaER6RF9yQncwc2txQmlGUnktdXBzNXFWVFhpREthbmlabF9vd0JCYTdyYkJnTUxaNkFsbl9tOGt0Qko4TWRmbjh0QnhQa1AtVkRESktTR2lR?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market - openPR.com","headline":"Emerging Growth Patterns Driving Expansion in the Anterior Uveitis Market","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOTFZEcHBORklQWkZ3RnZpMFFwTzN3MGNOOEo2Q1VYeHlKcnpMTkVfWHVMNnl5YkRTSGg1Tk1kZjlFU09HVGdlMlFFSDNpM2VjZFk3dTJBMUtEbEVGQ1JlbHJRS1IxdEpxcVVPUDdSN1RjbXNFRU9sdnNubDBKM2M1ajVacnlDZ0RzQWttYVZXRlQxdzExU1E?oc=5","date":"2024-03-05","type":"deal","source":"Seeking Alpha","summary":"Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed (NASDAQ:AUPH) - Seeking Alpha","headline":"Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed (NASDAQ:AUPH)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRkxsQnREcUNvUHFaa2RDdUppT0VaTzl2bmo1QVA5T1doRmNIQ283eS1OVHdQMVJDS3l2aWtEVHRFXzdWVFhvd1BWbWpVWWZjVjBFM1U4THF6ZDVMdWZJRHhfdkNtZ3dQSnU0dVh0UFNmV0JiOU55Z1lXM3F6ZE1lZ3ZpbEhHSGluY3BRTEl5MlJrd1NUdUZwSWtheGRlWVk?oc=5","date":"2023-03-01","type":"pipeline","source":"openPR.com","summary":"AI-powered algorithms to drive the Uveitis Treatment Market at a CAGR around 6% - openPR.com","headline":"AI-powered algorithms to drive the Uveitis Treatment Market at a CAGR around 6%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE5NSnFCSzhOS2pDc21jdUJQNXpubDY1V1ZsWDlleTcwRzV4Wmpkay1HYWhubjJjaFFTQnI5YnBPd2RVajd0MTdzRkZDYmVvT3RsV3QtZ2tyd1BhSzJRYjBTbVA0azQwa282d2dv?oc=5","date":"2022-03-23","type":"pipeline","source":"Straits Research","summary":"Uveitis Treatment Market Size, Share & Trends | Industry Report, 2033 - Straits Research","headline":"Uveitis Treatment Market Size, Share & Trends | Industry Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQQ0VsbDhCT3c5THpMQ1VmRy1SV2VNLTZ5NTAtcFBkWTNnTDJ3NDg4Wmxkd3ZlWWQ5aWtJWXp2dE9EeDk0SXo3LVAtNmw4czVXa0pQTEdDTmZhdUEyLUlIbmVLWHE0RXNpNFV0OW5qa2hrTldhSFhSdFQzSFpEOTJzVDNneXVObFRJZ1pBXzM1RHhQQUVBdktsOFF4aUdGTmtheHhpMDNzbS1MZ2ZvUmZQcXJjN2dYbUVzcUgyS3BJcUNMV2pIbFZHeFBRNldXWVcydFN6dDFYQUVZcG9ta0dfQW1zcmxCVzZYcHB4VENBV09RSUg1b0Y1dWYzTEJLSm4wdllCQlVuYnY?oc=5","date":"2021-11-08","type":"pipeline","source":"GlobeNewswire","summary":"EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy - GlobeNewswire","headline":"EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQS21RcjlrX20tSW4yRWlIbXhNQ3N6Wl9nRWpOa21QTlhrQXFvOUtuWERwcjZtLUYzY1NBTk11SFZnTVVBMGxVQTkyZ0NXbnRMaVNPbVVYRmFPZVZmcl9XdmhJUzUydWZrRWx3NjVIX0hlYlVkU3g5N05MU1FiekR2N2JYVW5TaWh3by02elAtY1RFM2VkandVWXJXWkVUSUNBUy1mOXdaeTZkMk9OVGNLX0tZRkZmcVlROGpuV0NPWWpyNjE2aVZ5RjhGZXVtNlJ1Tm10M2paanZiUHlDVHFEMThnWTlQZFlK?oc=5","date":"2021-05-05","type":"pipeline","source":"GlobeNewswire","summary":"Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031 - GlobeNewswire","headline":"Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPSWJKREhxUjVjaHFKN1ZYYkFZN2JWc19zWTVqbGZEd2MwYnNYM2U5OGdwMWRpSTlSZ3EzTTI2RmZ5WnJ0WmlhWEw2elJnX2NTdUxtZ0pmLXRacGxCQjFCbF9vOXctOGF5SGs0RXVZWlFXQXN2SkotOGF0NEh0N1FpUkltUllKWDRxblp3d3Rkb0lSejY5U2ZBQVB0V1FFeEgwMmphQ21mRy10MVFBTzFMdzctWXdRZEFfQkZjdTJqaw?oc=5","date":"2018-09-04","type":"trial","source":"Fierce Biotech","summary":"EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial - Fierce Biotech","headline":"EyeGate’s anti-inflammatory eye drug and electric delivery device fail phase 3 trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Zak00a2FUSmpaSUhCaWJ1Vkg1VWhVd0Z4cERObGd6azJPNGtmM3lVLTdHY3dubHBIM282Vk1WUHpEMk9RX05CWDQzWXdGY01OMk1oZElFTk9BRWRj?oc=5","date":"2017-07-21","type":"pipeline","source":"TradingView","summary":"EYEG Stock Fund Price and Chart — NASDAQ:EYEG - TradingView","headline":"EYEG Stock Fund Price and Chart — NASDAQ:EYEG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSWNiczVyMWtOTEFuOEVhenRYWkRZRVlHTk1WSmloUXpEaWRFZXgzYkI4M0Z5dUppVC02dHFaQjUydFN1N1Y2U29RcHNuU1hUSWkwOFdUaWNhWTIybzl5NVd0YVQyV2E0eUlEcmlGZnNEN3loYkhvc0trclAtYU9JQkxtenI3VTctdFBGOU5EaFZwaFFCcHhQeGZ3T25BT19lSkNEZ1c1TXZicjVNN3lNWEdOZEhqZw?oc=5","date":"2016-06-27","type":"deal","source":"Fierce Pharma","summary":"EyeGate Pharma inks registered direct stock offering deal to raise $3.77M - Fierce Pharma","headline":"EyeGate Pharma inks registered direct stock offering deal to raise $3.77M","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_2":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":16020000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":1652520,"period":"2018-12-31"},{"value":407518,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10780397,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-10835154,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":8696570,"cashHistory":[],"totalAssets":24253300,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}